145 related articles for article (PubMed ID: 37527610)
21. Unsaturated fatty acids bind Myc-Max transcription factor and inhibit Myc-Max-DNA complex formation.
Chung S; Park S; Yang CH
Cancer Lett; 2002 Dec; 188(1-2):153-62. PubMed ID: 12406560
[TBL] [Abstract][Full Text] [Related]
22. Omomyc expression in skin prevents Myc-induced papillomatosis.
Soucek L; Nasi S; Evan GI
Cell Death Differ; 2004 Sep; 11(9):1038-45. PubMed ID: 15143346
[TBL] [Abstract][Full Text] [Related]
23. A general method to design dominant negatives to B-HLHZip proteins that abolish DNA binding.
Krylov D; Kasai K; Echlin DR; Taparowsky EJ; Arnheiter H; Vinson C
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12274-9. PubMed ID: 9356439
[TBL] [Abstract][Full Text] [Related]
24. Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain.
Crouch DH; Fisher F; La Rocca SA; Goding CR; Gillespie DA
Nucleic Acids Res; 2005; 33(16):5235-42. PubMed ID: 16166655
[TBL] [Abstract][Full Text] [Related]
25. Specificity of DNA binding of the c-Myc/Max and ARNT/ARNT dimers at the CACGTG recognition site.
Swanson HI; Yang JH
Nucleic Acids Res; 1999 Aug; 27(15):3205-12. PubMed ID: 10454619
[TBL] [Abstract][Full Text] [Related]
26. Network pharmacology, molecular simulation, and binding free energy calculation-based investigation of Neosetophomone B revealed key targets for the treatment of cancer.
Khan A; Waheed Y; Kuttikrishnan S; Prabhu KS; El-Elimat T; Uddin S; Alali FQ; Agouni A
Front Pharmacol; 2024; 15():1352907. PubMed ID: 38434705
[TBL] [Abstract][Full Text] [Related]
27. Reconstitution of an E box-binding Myc:Max complex with recombinant full-length proteins expressed in Escherichia coli.
Farina A; Faiola F; Martinez E
Protein Expr Purif; 2004 Apr; 34(2):215-22. PubMed ID: 15003254
[TBL] [Abstract][Full Text] [Related]
28. The NMR solution structure of a mutant of the Max b/HLH/LZ free of DNA: insights into the specific and reversible DNA binding mechanism of dimeric transcription factors.
Sauvé S; Tremblay L; Lavigne P
J Mol Biol; 2004 Sep; 342(3):813-32. PubMed ID: 15342239
[TBL] [Abstract][Full Text] [Related]
29. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
[TBL] [Abstract][Full Text] [Related]
30. Mutational analysis of the spike protein of SARS-COV-2 isolates revealed atomistic features responsible for higher binding and infectivity.
Hanifa M; Salman M; Fatima M; Mukhtar N; Almajhdi FN; Zaman N; Suleman M; Ali SS; Waheed Y; Khan A
Front Cell Dev Biol; 2022; 10():940863. PubMed ID: 36733340
[No Abstract] [Full Text] [Related]
31. Repositioning of experimentally validated anti-breast cancer peptides to target FAK-PAX complex to halt the breast cancer progression: a biomolecular simulation approach.
Khan A; Shan S; Toor TF; Suleman M; Wang Y; Zhou J; Wei DQ
Mol Divers; 2023 Apr; 27(2):603-618. PubMed ID: 35635599
[TBL] [Abstract][Full Text] [Related]
32. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts.
Berg T; Cohen SB; Desharnais J; Sonderegger C; Maslyar DJ; Goldberg J; Boger DL; Vogt PK
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3830-5. PubMed ID: 11891322
[TBL] [Abstract][Full Text] [Related]
33. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors.
Nair SK; Burley SK
Cell; 2003 Jan; 112(2):193-205. PubMed ID: 12553908
[TBL] [Abstract][Full Text] [Related]
34. Biophysical and Structural Methods to Study the bHLHZip Region of Human c-MYC.
Zinzalla G
Methods Mol Biol; 2021; 2318():21-43. PubMed ID: 34019285
[TBL] [Abstract][Full Text] [Related]
35. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
Blackwood EM; Eisenman RN
Science; 1991 Mar; 251(4998):1211-7. PubMed ID: 2006410
[TBL] [Abstract][Full Text] [Related]
36. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max.
Gu W; Cechova K; Tassi V; Dalla-Favera R
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2935-9. PubMed ID: 8385351
[TBL] [Abstract][Full Text] [Related]
37. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
[TBL] [Abstract][Full Text] [Related]
38. Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells.
Grinberg AV; Hu CD; Kerppola TK
Mol Cell Biol; 2004 May; 24(10):4294-308. PubMed ID: 15121849
[TBL] [Abstract][Full Text] [Related]
39. Bioinformatics analysis of the differences in the binding profile of the wild-type and mutants of the SARS-CoV-2 spike protein variants with the ACE2 receptor.
Suleman M; Yousafi Q; Ali J; Ali SS; Hussain Z; Ali S; Waseem M; Iqbal A; Ahmad S; Khan A; Wang Y; Wei DQ
Comput Biol Med; 2021 Nov; 138():104936. PubMed ID: 34655895
[TBL] [Abstract][Full Text] [Related]
40. Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers.
Maltais L; Montagne M; Bédard M; Tremblay C; Soucek L; Lavigne P
PLoS One; 2017; 12(3):e0174413. PubMed ID: 28350847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
